Prednisone
| Evidence Level: L2 | Predicted Indications: 9 |
Table of Contents
Prednisone: Alopecia areata
One-Sentence Summary
Prednisone is an oral systemic glucocorticoid that suppresses T-cell activation and inflammatory cytokine production. The TxGNN model predicts it may be useful for alopecia areata, and the data compiled for this report include no registered clinical trials and 20 publications, among them one double-blind randomised trial of low-dose prednisone combined with methotrexate. Evidence is mostly small cohorts, case series and older reports.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Alopecia areata |
| TxGNN Prediction Score | 0.9999 |
| Evidence Level | L2 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism of action data for prednisone are not available in the data compiled for this report. From general pharmacology, prednisone is a systemic glucocorticoid with broad immunosuppressive and anti-inflammatory effects.
Alopecia areata is a T-cell-mediated autoimmune attack on the hair follicle that breaks down the follicle’s immune privilege. By suppressing T-cell activation and inflammatory cytokine production, prednisone could plausibly interrupt this process. Systemic corticosteroids have been used for this condition since the 1950s to 1970s.
There are important limits. Hair regrowth is often not sustained after the drug is withdrawn, and long-term systemic steroid toxicity restricts use. More recent work uses low-dose prednisone as an adjunct to methotrexate or baricitinib rather than as a stand-alone treatment.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36884234 | 2023 | RCT (2-step, double-blind) | JAMA Dermatology | Methotrexate alone vs methotrexate plus low-dose prednisone in alopecia areata totalis or universalis |
| 1444500 | 1992 | Randomised controlled trial | Archives of Dermatology | 32 patients; 6-week prednisone taper followed by 2% topical minoxidil or vehicle |
| 37467740 | 2023 | Case series | Clinical and Experimental Dermatology | Baricitinib plus low-dose corticosteroids gave major improvement in eight patients with very severe disease |
| 41958306 | 2026 | Retrospective case series | J Eur Acad Dermatol Venereol | Baricitinib with low-dose prednisone in very severe alopecia areata |
| 1444509 | 1992 | Review | Archives of Dermatology | Review of therapy, efficacy, safety and mechanism; studies too heterogeneous for meaningful comparison |
| 8996277 | 1997 | Clinical study | J Am Acad Dermatol | Systemic cyclosporine with low-dose prednisone in chronic severe disease |
| 20804894 | 2010 | Cohort | Ann Dermatol Venereol | Efficacy and safety of once-monthly oral prednisone pulse |
| 791152 | 1976 | Cohort follow-up | Archives of Dermatology | 18 patients on alternate-day prednisone; initial response but long-term benefit not substantial, with numerous side effects |
| 4571041 | 1973 | Cohort | Archives of Dermatology | Immunologic studies and prednisone treatment |
| 4684625 | 1973 | Case report | Canadian Medical Association Journal | Systemic corticosteroids in alopecia totalis; shorter courses may suffice in some cases |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 13944X | Panafcort | Tablet 5 mg (oral) | Not listed in the data compiled for this report |
Safety Considerations
- Drug Interactions: The interaction search returned 100 records, of which the main ones are listed. A major-level interaction was recorded with adalimumab. Moderate-level interactions include zidovudine, isotretinoin, acarbose, acebutolol, acetazolamide, ketorolac, nifedipine, ibuprofen, ethinylestradiol, butalbital, albiglutide, aldesleukin, alefacept, alemtuzumab and aliskiren; tetanus toxoid vaccine also has a moderate-level record. Formoterol and salbutamol interactions are minor.
- Other safety points from the literature: Older studies report acne, obesity, lenticular opacities and mild hypertension with prolonged systemic prednisone, and relapse after withdrawal.
Please refer to the TGA-approved Product Information (PI) for full warnings and contraindications.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Alopecia areata has a plausible immune mechanism for glucocorticoid action and a double-blind randomised trial studying low-dose prednisone as an adjunct. However, regrowth is often not sustained, long-term steroid toxicity is a concern, and the evidence is mainly small or older studies rather than completed Phase 3 trials.
To proceed, the following is needed:
- TGA Product Information warnings and contraindications (not yet available in the compiled data)
- Mechanism of action data from DrugBank
- Controlled data on prednisone as part of a regimen, with relapse after withdrawal as an outcome
- A monitoring plan for steroid adverse effects, with attention to hypertension, hyperglycaemia and infection risk, and review of interacting medicines such as adalimumab
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.